Skip to main content

Advertisement

SpringerLink
Log in

Update in Women’s Health

  • Updates
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. U.S. Food and Drug Administration. A public health advisory: Ortho Evra 2005. Available at: http://www.fda.gov/cder/drug/infopage/orthoevra/default.htm.

  2. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35mcg of ethinyl estradiol. Contraception. 2006;73(March):223–8.

    Article  PubMed  CAS  Google Scholar 

  3. GlaxoSmithKline Clinical Trial Register. Available at: http://ctr.gsk.co.uk/medicinelist.asp. and www.gsk.com/media/paroxetine/mi_letter_paroxetine_pregnancy.pdf.

  4. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.

    Article  PubMed  CAS  Google Scholar 

  5. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.

    Article  PubMed  CAS  Google Scholar 

  6. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372–83.

    Article  PubMed  CAS  Google Scholar 

  7. Beresford SA, Johnson KC, Ritenbaugh C, et al. Low-fat dietary pattern and risk of colorectal cancer. The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:643–54.

    Article  PubMed  CAS  Google Scholar 

  8. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease. The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:655–66.

    Article  PubMed  CAS  Google Scholar 

  9. Porthouse J, Cockayne S, King C, et al. Randomized controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for the prevention of fractures in primary care. Br Med J. 2005;300:1003–8.

    Article  Google Scholar 

  10. The Record Trial Group. Oral vitamin D3 and calcium for the secondary prevention of low-trauma fractures in elderly people (randomized evaluation of calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365:1621–28.

    Article  CAS  Google Scholar 

  11. Avenell A, Gillespie WJ, Gillespie LD, O’Connell DL. Vitamin D and Vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005;(3)CD000227.

  12. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol. 2005;105:944–52.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors are grateful to Jennifer L. Hardman, BS, PharmD, for helpful advice about article selection and interpretation.

Author information

Authors and Affiliations

  1. Division of General Internal Medicine, Department of Medicine, Medical College of Wisconsin, 9200 West Wisconsin Avenue, FEC, Suite 4200, Milwaukee, WI, 53226, USA

    Julie L. Mitchell MD, MS, Susan L. Davids MD, MPH, Ann B. Nattinger MD, MPH & Joan M. Neuner MD, MPH

  2. Division of General Internal Medicine, University of Nevada School of Medicine, Reno, NV, USA

    Jennifer R. Zebrack MD

Authors
  1. Julie L. Mitchell MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer R. Zebrack MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan L. Davids MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ann B. Nattinger MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joan M. Neuner MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie L. Mitchell MD, MS.

Additional information

Potential Financial Conflicts of Interest

None disclosed.

Appendices

APPENDIX

Table 3 summarizes important women’s health articles published between April 2005 and February 2006 not described in the text. Table 4 summarizes reports on women’s health medications.

Table 3 Summary of women’s health articles (not described in text)
Full size table
Table 4 Brief reports on women’s health medications: new information on administration and adverse effect profile for unique preparations
Full size table

Appendix References

1. Murphy PA, Kern SE, Stanczyk FZ, et al. Interaction of St. John’s Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71:402–8.

2. Griffith WF, Stuart GS, Gluck KL, et al. Vaginal speculum lubrication and its effects on cervical cytology and microbiology. Contraception. 2005;72(1):60–4.

3. Hathaway JK, Pathak PK, Maney R. Is liquid-based Pap testing affected by water-based lubricant? Obstet Gynecol. 2006;107(1):66–70.

4. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol. 2006;107(1):18–27.

5. Turrentine MA. Single-dose fluconazole for vulvovaginal candidiasis: Impact on prothrombin time in women taking warfarin. Obstet Gynecol. 2006;107(2):310–3.

6. Richards D, Toop L, Chambers S, et al. Response to antibiotics of women with symptoms of urinary tract infection but negative dipstick urine test results: double-blind randomized controlled trial. Br Med J. 2005;331:143–6.

7. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.

8. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372–83.

9. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.

10. Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, et al. Low-fat dietary pattern and risk of colorectal cancer. The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:643–54.

11. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, et al. Low-fat dietary pattern and risk of cardiovascular disease. The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:655–66.

12. Howard BV, Manson JE, Stefanick ML, Beresford SA, Frank G, et al. Low-fat dietary pattern and weight change over 7 years. The Women’s Health Initiative Modification Trial. JAMA. 2006;295:39–49.

13. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk. A systematic review. JAMA. 2006;295:403–15.

14. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.

15. Porthouse J, Cockayne S, King C, et al. Randomized controlled trial of calcium and supplementation with cholecalciferol (Vitamin D3) for the prevention of fractures in primary care. Brit Med J. 2005;300:1003–8.

16. Avenell A, Gillespie WJ, Gillespie LD, O’Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2005;(3)CD000227.

17. The Record Trial Group. Oral vitamin D3 and calcium for the secondary prevention of low-trauma fractures in elderly people (randomized evaluation of calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365:1621–28.

18. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–64.

19. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353(6): 566–75.

20. Quandt SA, Thompson DE, Schneider SL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density t score of −1.6 to −2.5 at the femoral neck: The Fracture Intervention Trial. Mayo Clin Proc. 2005;80:343–9.

21. Schousboe JT, Nyman JA, Kane RL, Ensrud LKE. Cost effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142(9):734–42.

22. Rondoni N, Newman AB, Vittinghof E, et al. Subclinical hypothyroidism and the risk of heart failure. Other cardiovascular events and death. Arch Intern Med. 2005;165:2460–6.

23. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:2467–72.

24. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033–41.

25. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005;294:183–93.

26. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol. 2005;105:1063–73.

27. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet. 2005;366:818–24.

28. Stearns V, Johnson MD, Rae JM, Morocho A, Bhargava AP, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758–64.

29. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23:6919–30.

30. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005;105:1074–83.

31. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruewald J, Wernecke KD. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial. Obstet Gynecol. 2006;107:247–55.

32. Lemaitre RN, Weiss NS, Smith NL, et al. Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med. 2006;166:399–404.

33. Berger JS, Roncaglioni M, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–13.

34. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105:944–52.

35. Davis SR, Davidson SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294: 91–6.

36. Stewart FH, Kaunitz AM, LaGuardia KD, et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol. 2005;105(6):1389–96.

37. Hout J, Miller L, Verhoeven CH, et al. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol. 2005;106(3):473–82.

38. Lakha F, Henderson C, Glasier A. The acceptability of self-administration of subcutaneous Depo-Provera. Contraception. 2005;72:14–8.

39. Balkus J, Miller L. Same-day administration of depot-medroxyprogestrone acetate injection: a retrospective chart review. Contraception. 2005;71:395–8.

40. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112:1979–84.

41. Waetjen LE, Brown JS, Vittinghoff E, Ensrud KE, Pinkerton JA, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstet Gynecol. 2005;106:946–52.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitchell, J.L., Zebrack, J.R., Davids, S.L. et al. Update in Women’s Health. J GEN INTERN MED 22, 1351–1364 (2007). https://doi.org/10.1007/s11606-006-0066-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-006-0066-3

KEY WORDS

Search

Navigation